Edesa Biotech Buchwert je Aktie
Was ist das Buchwert je Aktie von Edesa Biotech?
Buchwert je Aktie von Edesa Biotech, Inc. ist 1.77
Was ist die Definition von Buchwert je Aktie?
Der Buchwert pro Aktie ist das Vermögen eines Unternehmens abzüglich der Verbindlichkeiten geteilt durch die Anzahl der ausstehenden Aktien.
The book value of a company is the value of its assets according to its balance sheet account balance. For assets, the value is based on the original cost of the asset less any depreciation, amortization or impairment costs made against the asset. Traditionally, a company's book value is its total assets minus intangible assets and liabilities. However, in practice, depending on the source of the calculation, book value may variably include goodwill, intangible assets, or both. The value inherent in its workforce, part of the intellectual capital of a company, is always ignored. The book value of a company may be also referred as with the term net asset value.
The book value per share is the the balance sheet equity value divided by the number of shares outstanding at the date of the balance sheet. Book value per share can be used to generate a measure of comprehensive earnings, when the opening and closing values are reconciled. The sale of shares/units by a business increases the total book value. Book value per share will increase if the additional shares are issued at a price higher than the pre-existing book value per share. The purchase of its own shares by a business will decrease total book value. Book value per share will decrease if more is paid for them than was received when originally issued. Dividends paid out will decrease book value per share value.
Buchwert je Aktie von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Edesa Biotech
Was macht Edesa Biotech?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
Unternehmen mit buchwert je aktie ähnlich Edesa Biotech
- Sky Solar hat Buchwert je Aktie von 1.76
- Patriot National Bancorp Inc hat Buchwert je Aktie von 1.76
- INmune Bio hat Buchwert je Aktie von 1.77
- Extraction Oil & Gas hat Buchwert je Aktie von 1.77
- Logic Instrument S.A hat Buchwert je Aktie von 1.77
- LINK Mobility ASA hat Buchwert je Aktie von 1.77
- Edesa Biotech hat Buchwert je Aktie von 1.77
- Lifestyle International hat Buchwert je Aktie von 1.77
- Naked Wines plc hat Buchwert je Aktie von 1.77
- Dicerna Pharmaceuticals Inc hat Buchwert je Aktie von 1.77
- Vulcan Resources hat Buchwert je Aktie von 1.77
- Gold Rush Cariboo hat Buchwert je Aktie von 1.77
- Westwater Resources Inc hat Buchwert je Aktie von 1.77